This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- Radiation Safety Considerations and Clinical Advantages of {alpha}-Emitting Therapy Radionuclides
- 124I-huA33 Antibody Uptake Is Driven by A33 Antigen Concentration in Tissues from Colorectal Cancer Patients Imaged by Immuno-PET
- Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease
- A Pharmacokinetic Model for Radioimmunotherapy Delivered Through Cerebrospinal Fluid for the Treatment of Leptomeningeal Metastases
- Multimodality Therapy: Potentiation of High Linear Energy Transfer Radiation with Paclitaxel for the Treatment of Disseminated Peritoneal Disease
- Further Explorations of Cellular Uptake of Radioactivity
- Potentiation of High-LET Radiation by Gemcitabine: Targeting HER2 with Trastuzumab to Treat Disseminated Peritoneal Disease
- Targeted {alpha}-Particle Therapy of Microscopic Disease: Providing a Further Rationale for Clinical Investigation
- Log Normal Distribution of Cellular Uptake of Radioactivity: Implications for Biologic Responses to Radiopharmaceuticals
- Abbreviated Chemotherapy With Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab for Untreated Follicular Lymphoma
- Liposome-Mediated Radiotherapeutics Within Avascular Tumor Spheroids: Comparative Dosimetry Study for Various Radionuclides, Liposome Systems, and a Targeting Antibody
- Targeting of HER2 Antigen for the Treatment of Disseminated Peritoneal Disease
- Impact of Nodal Regression on Radiation Dose for Lymphoma Patients After Radioimmunotherapy